Last reviewed · How we verify
NCT05351580: DiSCERN
DiSCERN: Advanced PD Therapy Candidacy and Evaluation System
trial testing DiSCERN in Parkinson Disease in 26 participants. Completed in 30 June 2024.
30 June 2024
Quick facts
| Lead sponsor | Great Lakes NeuroTechnologies Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 26 |
| Start date | 21 July 2022 |
| Primary completion | 30 June 2024 |
| Estimated completion | 30 June 2024 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- DiSCERN
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
Great Lakes NeuroTechnologies Inc.
Who can join
18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To collect data to develop models that identify when patients with advanced Parkinson's disease (PD) are not responding well to their current therapy and may be ready to consider advanced therapy and when patients receiving advanced therapy are not responding well and need a therapy adjustment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
SmartWear body sensors for neurological and neurosurgical patients: A review of current and future technologies.
Gupta N, Kasula V, Sanmugananthan P, Panico N, et al · · 2024 · cited 5× · PMID 38033718 · DOI 10.1016/j.wnsx.2023.100247
Verify or expand the search:
- PubMed search for NCT05351580
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Great Lakes NeuroTechnologies Inc. trials
Trials by the same sponsor.
- NCT04121793 — Objective Quality of Life Detection Validation · completed
- NCT04142528 — Patient-Centered PD Ambulatory Monitoring System · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05351580 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Great Lakes NeuroTechnologies Inc.
- Last refreshed: 26 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05351580.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing